Takeda's Livtencity Approved For Refractory CMV Infection In Transplant Patients
Executive Summary
Maribavir is the first antiviral agent targeting and inhibiting the pUL97 protein kinase, as well as Takeda's second new molecular entity approved by FDA this year.
You may also be interested in...
A Year And A Half After Giving Up On TAK-721, Takeda Seeks Approval In EoE
The US FDA rejected TAK-721 for eosinophilic esophagitis (EoE) in 2021, requiring another study, and Takeda ended development in 2022, but in a newly accepted NDA it is seeking a short-term treatment indication.
Gilead’s Lenacapavir, Takeda’s Maribavir Due For Oral Explanations At EMA
The sponsors of four drugs were due or possibly due to appear before the European Medicines Agency to explain why their respective products merit EU-wide approval.
Budesonide CRL Another Setback For Takeda’s ‘Wave 1’ Pipeline
Setback for company's near-term launch goals and US patients with rare esophageal inflammatory condition as regulator asks for additional clinical data.